share_log

Dr. Reddy's Launches Drug-Free Migraine Management Device Nerivio In Europe Following Successful Launch In India

Benzinga ·  Apr 10 07:08

Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, hereafter referred to as ", Dr. Reddy', s", )), a global pharmaceutical company, announced the launch of the drug-free non-invasive migraine management wearable device Nerivio in Germany through its step-down subsidiary betapharm. The launch marks the company's entry into digital therapeutics in Europe. Nerivio is approved by the United States Food and Drug Administration (USFDA), and is CE-mark certified in Europe.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment